Ipsilateral Upper-Limb Lymphedema After COVID-19 Vaccine Booster: Reply.
作者信息
Tang Charlene Yu Lin, Chua Wei Ming
机构信息
Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore
出版信息
Clin Nucl Med. 2023 Sep 1;48(9):837. doi: 10.1097/RLU.0000000000004741. Epub 2023 Jun 6.
Abstract
摘要
相似文献
1
Ipsilateral Upper-Limb Lymphedema After COVID-19 Vaccine Booster: Reply.新冠疫苗加强针接种后同侧上肢淋巴水肿：回复
Clin Nucl Med. 2023 Sep 1;48(9):837. doi: 10.1097/RLU.0000000000004741. Epub 2023 Jun 6.
2
Re: Ipsilateral Upper-Limb Lymphedema After COVID-19 Vaccine Booster.关于：新冠疫苗加强针接种后同侧上肢淋巴水肿
Clin Nucl Med. 2023 Sep 1;48(9):836-837. doi: 10.1097/RLU.0000000000004610. Epub 2023 Mar 1.
3
Ipsilateral Upper-Limb Lymphedema After COVID-19 Vaccine Booster.接种 COVID-19 疫苗加强针后同侧上肢淋巴水肿。
Clin Nucl Med. 2023 Mar 1;48(3):264-265. doi: 10.1097/RLU.0000000000004470. Epub 2022 Oct 27.
4
Breast carcinoma presenting with upper limb lymphedema - A rare case.乳腺癌致上肢淋巴水肿——罕见病例报告。
Breast Dis. 2023;42(1):395-399. doi: 10.3233/BD-230022.
5
Reply to: Letter comments on: Correlation of ICG lymphography and lymphoscintigraphy severity stage in secondary upper limb lymphedema.回复：关于《吲哚菁绿淋巴造影与淋巴闪烁造影在继发性上肢淋巴水肿严重程度分期中的相关性》的信件评论
J Plast Reconstr Aesthet Surg. 2021 Jul;74(7):1633-1701. doi: 10.1016/j.bjps.2021.02.010. Epub 2021 Mar 22.
6
Upper extremity function and quality of life in patients with breast cancer related lymphedema.乳腺癌相关淋巴水肿患者的上肢功能与生活质量
Vojnosanit Pregl. 2016 Sep;73(9):825-30. doi: 10.2298/VSP150208075B.
7
Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity.定量放射性核素淋巴闪烁显像可预测上肢乳腺癌相关淋巴水肿手法淋巴引流治疗的效果。
Nucl Med Commun. 2002 Dec;23(12):1171-5. doi: 10.1097/00006231-200212000-00004.
8
[Risk factors for developing upper limb lymphedema after breast cancer treatment].[乳腺癌治疗后发生上肢淋巴水肿的危险因素]
Bull Cancer. 2006 Oct;93(10):1001-6.
9
Transient lower extremity lymphedema following COVID-19 vaccination: A case report.接种 COVID-19 疫苗后一过性下肢淋巴水肿：病例报告。
Medicine (Baltimore). 2021 Dec 3;100(48):e28092. doi: 10.1097/MD.0000000000028092.
10
Discussion of relationships among changes of pathological indicators, postoperative lymphedema of the upper limb, and prognosis of patients with breast cancer.探讨乳腺癌患者病理指标变化、术后上肢淋巴水肿与预后的关系。
Biosci Rep. 2019 Apr 16;39(4). doi: 10.1042/BSR20190231. Print 2019 Apr 30.
本文引用的文献
1
Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.贝鲁特大学社区报告的辉瑞/生物新技术（BNT162b2） COVID-19 疫苗的副作用。
BMC Infect Dis. 2023 Jan 5;23(1):5. doi: 10.1186/s12879-022-07974-3.
2
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
3
Ipsilateral Upper-Limb Lymphedema After COVID-19 Vaccine Booster.接种 COVID-19 疫苗加强针后同侧上肢淋巴水肿。
Clin Nucl Med. 2023 Mar 1;48(3):264-265. doi: 10.1097/RLU.0000000000004470. Epub 2022 Oct 27.
4
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.全球首例 COVID-19 疫苗接种一年的影响：一项数学建模研究。
Lancet Infect Dis. 2022 Sep;22(9):1293-1302. doi: 10.1016/S1473-3099(22)00320-6. Epub 2022 Jun 23.
5
Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis.接种疫苗以降低新冠病毒感染患者的重症率和死亡率：一项系统评价与荟萃分析
Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1770-1776. doi: 10.26355/eurrev_202203_28248.
6
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.估算2019冠状病毒病大流行造成的超额死亡率：2020 - 2021年与2019冠状病毒病相关死亡率的系统分析
Lancet. 2022 Apr 16;399(10334):1513-1536. doi: 10.1016/S0140-6736(21)02796-3. Epub 2022 Mar 10.
7
Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study.年龄是 COVID-19 相关住院死亡率的主要决定因素，而既往合并症的影响最小，这是一项回顾性队列研究。
BMC Geriatr. 2022 Mar 5;22(1):184. doi: 10.1186/s12877-021-02673-1.
8
Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database.关于Moderna、辉瑞和牛津-阿斯利康新冠疫苗报告的血栓形成不良事件：欧洲药物警戒数据库中发生率和临床结果的比较
Vaccines (Basel). 2021 Nov 15;9(11):1326. doi: 10.3390/vaccines9111326.
9
Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.新型冠状病毒2疫苗在真实世界研究中的有效性和安全性：一项系统评价与荟萃分析
Infect Dis Poverty. 2021 Nov 14;10(1):132. doi: 10.1186/s40249-021-00915-3.
10
Acute myocardial infarction and myocarditis following COVID-19 vaccination.接种新冠疫苗后出现急性心肌梗死和心肌炎。
QJM. 2023 Apr 29;116(4):279-283. doi: 10.1093/qjmed/hcab252.
Zotero 插件